Arenavirus antigen

Arenavirus antigens are the structural and non-structural proteins encoded by viruses in the Arenaviridae family, which include significant human pathogens such as Lassa virus (LASV) and Junin virus (JUNV) (Source: UniProt). The primary antigenic targets for therapeutic intervention are the glycoprotein complex (GPC), responsible for viral attachment and entry, and the nucleoprotein (NP), which is the most abundant viral protein and a major target for the host immune response (Source: PubMed). These antigens play critical roles in the viral life cycle, including genome packaging, replication, and evasion of the host's innate immune system by inhibiting interferon signaling (Source: NCBI). In the context of disease, these proteins are responsible for the pathogenesis of viral hemorrhagic fevers and meningitis (Source: WHO). Therapeutic strategies targeting these antigens include the development of neutralizing monoclonal antibodies, such as Arevirumab, which bind to the GPC to prevent viral entry, and vaccines like Candid #1 designed to elicit protective immune responses (Source: CDC). While some small-molecule inhibitors like ribavirin target the viral polymerase (L protein), most antigen-focused therapies aim to neutralize the virus or prime the immune system for rapid clearance (Source: Nature Reviews Microbiology).

Other names

Arenaviridae antigensArenaviral proteinsViral structural proteinsArenavirus glycoprotein complexArenavirus nucleoprotein

Neutralization of viral entry by binding to the glycoprotein complex; inhibition of viral RNA-dependent RNA polymerase (L protein) activity to halt replication; induction of humoral and cellular immune responses through vaccination.